RIVENDELL GROUP LLP lobbying for GENENTECH

Filing 1st Quarter - Termination

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 24, 2026

Income

$30,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Representation ended

Feb 28, 2026

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 2

MATTHEW LAWRENCE BERZOK

Previously held: LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
NICK KOLOVOS

Previously held: LA and Counsel, Rep. Anna Eshoo

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues relating to privacy and securing the data of and personal information of consumers General education on policies effecting development of pharmaceuticals, FDA approval and reimbursement.

Medicare/Medicaid

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease;